Bendamustine Administration

Bendamustine Administration. PDF filesubsequent doses can be given by subcutaneous administration 1400 mg (fixed dose in 117 mL) on day 1 or 2 whenever possible but not later than 72 h after day 1 of bendamustine Subcutaneous over 5 minutes into abdominal wall ‡ Observe for 15 minutes after administration *Start the (first dose) initial infusion at 50 mg/h and after 1 hour increase by 50 mg/h every 30.

PDF file24 Preparation for Intravenous Administration Bendamustine hydrochloride for injection is a cytotoxic drug Follow applicable special handling and disposal procedures 1 Bendamustine Hydrochloride for Injection (25 mg/vial or 100 mg/vial lyophilized powder) If a closed system transfer device or adapter that contains polycarbonate or ABS is to be used as supplemental.

Bendamustine + Rituximab, Bcell Lymphoma …

PDF fileBendamustine is a bifunctional mechlorethamine derivative containing a purinelike benzimidazole ring Its exact mechanism of action is unknown but it may cause apoptotic and nonapoptotic death of malignant cells by damaging both single and doublestrand DNA increasing the expression of proapoptotic genes and inhibiting mitotic control Bendamustine.

Bendamustine Drug Informatio Chemocare

PDF fileo Treatment with bendamustine in the relapsed setting For Cycle 1 Days 1 and 2 oBINutuzumab administration is 6 to 8 hours on average Treatment should be booked for earliest morning appointment Administration site restrictions are in place for oBINutuzumab Cycle 1 Days 1 and 2 must be administered at CCMB.

Bendamustine (Intravenous Route) Description and Brand

For patients with indolent NHL bendamustine is administered as a 60minute IV infusion on days 1 and 2 of a 21day cycle for up to 8 cycles The recommended dose is 120 mg/m 2 A patient’s dose of bendamustine is placed in a 500mL infusion bag of 09% Sodium Chloride Injection USP (normal saline).